Literature DB >> 18573583

BCG vaccination and WHO's global strategy for tuberculosis control 1948-1983.

Niels Brimnes1.   

Abstract

Mass vaccination with BCG against tuberculosis has been one of the major health interventions of WHO since the Second World War. This article traces the history of the controversial BCG vaccine from its adoption by WHO in 1948 up to 1983. In 1948, there was no clear scientific evidence to support the vaccine, and its adoption by WHO seems to have been urged by the existence of the UNICEF funded 'International Tuberculosis Campaign' and a fear of a threatening global epidemic. Moreover, BCG fitted well with the post Second World War perception of public health interventions. The vaccine was not systematically reviewed by WHO until 1959, and this review appears to have been biased in favour of the vaccine. In 1979 the results from the South Indian Chingleput trial, which showed no protective effect of BCG against pulmonary tuberculosis in adults, prompted WHO to change the arguments for recommending the vaccine. Since 1983 BCG has been recommended with specific reference to its protective effect against severe forms of childhood tuberculosis. The story of the BCG vaccine and WHO is a story of medical uncertainty, institutional inertia, strategic obduracy, and not least, hope.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573583     DOI: 10.1016/j.socscimed.2008.05.016

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  3 in total

1.  Rational design of multiple TB antigens TB10.4 and TB10.4-Ag85B as subunit vaccine candidates against Mycobacterium tuberculosis.

Authors:  Shuai Shi; Lan Yu; Dengyun Sun; Jian Liu; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-10-28       Impact factor: 4.200

2.  Between Donor Interest, Global Models and Local Conditions: Treatment and Decision-Making in the Somalia-Finland Tuberculosis Control Project, 1981-3.

Authors:  Kaisa Harju
Journal:  Med Hist       Date:  2020-01       Impact factor: 1.419

3.  PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B.

Authors:  Shuai Shi; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-12-19       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.